South Korea · Delayed Price · Currency is KRW Verve Therapeutics Statistics
Total Valuation
KBIO COMPANY has a market cap or net worth of KRW 34.88 billion. The enterprise value is 37.01 billion.
| Market Cap | 34.88B |
| Enterprise Value | 37.01B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO COMPANY has 115.50 million shares outstanding. The number of shares has increased by 6.78% in one year.
| Current Share Class | 115.50M |
| Shares Outstanding | 115.50M |
| Shares Change (YoY) | +6.78% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 77.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.43 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | 16.91 |
| P/OCF Ratio | 16.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.77, with an EV/FCF ratio of 17.95.
| EV / Earnings | -5.28 |
| EV / Sales | 0.46 |
| EV / EBITDA | 39.77 |
| EV / EBIT | n/a |
| EV / FCF | 17.95 |
Financial Position
The company has a current ratio of 5.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.93 |
| Quick Ratio | 5.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 1.23 |
| Debt / FCF | 0.55 |
| Interest Coverage | -2.73 |
Financial Efficiency
Return on equity (ROE) is -8.62% and return on invested capital (ROIC) is -0.06%.
| Return on Equity (ROE) | -8.62% |
| Return on Assets (ROA) | -0.06% |
| Return on Invested Capital (ROIC) | -0.06% |
| Return on Capital Employed (ROCE) | -0.11% |
| Revenue Per Employee | 2.45B |
| Profits Per Employee | -212.45M |
| Employee Count | 33 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 11.99 |
Taxes
In the past 12 months, KBIO COMPANY has paid 132.02 million in taxes.
| Income Tax | 132.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.63% in the last 52 weeks. The beta is 0.94, so KBIO COMPANY's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +18.63% |
| 50-Day Moving Average | 278.74 |
| 200-Day Moving Average | 257.76 |
| Relative Strength Index (RSI) | 62.18 |
| Average Volume (20 Days) | 1,437,440 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO COMPANY had revenue of KRW 81.01 billion and -7.01 billion in losses. Loss per share was -60.92.
| Revenue | 81.01B |
| Gross Profit | 12.73B |
| Operating Income | -119.84M |
| Pretax Income | -10.03B |
| Net Income | -7.01B |
| EBITDA | 930.66M |
| EBIT | -119.84M |
| Loss Per Share | -60.92 |
Balance Sheet
The company has 50.09 billion in cash and 1.14 billion in debt, giving a net cash position of 48.95 billion or 423.79 per share.
| Cash & Cash Equivalents | 50.09B |
| Total Debt | 1.14B |
| Net Cash | 48.95B |
| Net Cash Per Share | 423.79 |
| Equity (Book Value) | 107.27B |
| Book Value Per Share | 486.54 |
| Working Capital | 61.26B |
Cash Flow
In the last 12 months, operating cash flow was 2.14 billion and capital expenditures -79.96 million, giving a free cash flow of 2.06 billion.
| Operating Cash Flow | 2.14B |
| Capital Expenditures | -79.96M |
| Free Cash Flow | 2.06B |
| FCF Per Share | 17.86 |
Margins
Gross margin is 15.71%, with operating and profit margins of -0.15% and -8.65%.
| Gross Margin | 15.71% |
| Operating Margin | -0.15% |
| Pretax Margin | -12.38% |
| Profit Margin | -8.65% |
| EBITDA Margin | 1.15% |
| EBIT Margin | -0.15% |
| FCF Margin | 2.55% |
Dividends & Yields
KBIO COMPANY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.78% |
| Shareholder Yield | n/a |
| Earnings Yield | -20.10% |
| FCF Yield | 5.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 27, 2017. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 27, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
KBIO COMPANY has an Altman Z-Score of 2.11 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.11 |
| Piotroski F-Score | 4 |